Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Price:
12.87 USD
-5.44%
Market Closed
Updated:
May 10, 2024
Balance Sheet
Balance Sheet Decomposition
Y-mAbs Therapeutics Inc
Y-mAbs Therapeutics Inc
| Current Assets | 111.1m |
| Cash & Short-Term Investments | 78.6m |
| Receivables | 22.5m |
| Other Current Assets | 10m |
| Non-Current Assets | 16.8m |
| PP&E | 1.6m |
| Intangibles | 2.6m |
| Other Non-Current Assets | 12.5m |
| Current Liabilities | 20.1m |
| Accounts Payable | 6.1m |
| Accrued Liabilities | 14.1m |
| Non-Current Liabilities | 6.8m |
| Other Non-Current Liabilities | 6.8m |
Balance Sheet
Y-mAbs Therapeutics Inc
Y-mAbs Therapeutics Inc
Currency: USD
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
17
|
91
|
148
|
207
|
115
|
182
|
106
|
79
|
|
| Cash Equivalents |
17
|
91
|
148
|
207
|
115
|
182
|
106
|
79
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
8
|
13
|
22
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
8
|
13
|
22
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
6
|
7
|
5
|
|
| Other Current Assets |
0
|
1
|
4
|
5
|
8
|
8
|
6
|
5
|
|
| Total Current Assets |
17
|
91
|
152
|
212
|
122
|
202
|
130
|
111
|
|
| PP&E Net |
0
|
0
|
0
|
4
|
6
|
6
|
2
|
2
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
2
|
3
|
3
|
|
| Other Long-Term Assets |
0
|
1
|
0
|
0
|
3
|
3
|
6
|
12
|
|
| Total Assets |
17
N/A
|
92
+432%
|
152
+65%
|
216
+42%
|
132
-39%
|
213
+61%
|
142
-34%
|
128
-10%
|
|
| Liabilities | |||||||||
| Accounts Payable |
2
|
6
|
6
|
9
|
9
|
14
|
14
|
6
|
|
| Accrued Liabilities |
1
|
2
|
3
|
5
|
10
|
14
|
14
|
14
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
3
|
8
|
9
|
14
|
20
|
28
|
28
|
20
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
2
|
2
|
2
|
4
|
7
|
5
|
4
|
7
|
|
| Total Liabilities |
5
N/A
|
10
+92%
|
11
+14%
|
18
+54%
|
26
+50%
|
33
+25%
|
32
-2%
|
27
-17%
|
|
| Equity | |||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
22
|
42
|
85
|
166
|
285
|
341
|
436
|
457
|
|
| Additional Paid In Capital |
34
|
124
|
225
|
365
|
392
|
519
|
544
|
558
|
|
| Other Equity |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
|
| Total Equity |
12
N/A
|
82
+579%
|
141
+71%
|
199
+42%
|
106
-47%
|
180
+70%
|
109
-39%
|
101
-8%
|
|
| Total Liabilities & Equity |
17
N/A
|
92
+432%
|
152
+65%
|
216
+42%
|
132
-39%
|
213
+61%
|
142
-34%
|
128
-10%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
33
|
33
|
34
|
40
|
41
|
44
|
44
|
44
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
